In a study by Shin et al., these mutations were analyzed in patients with melanoma or CRC and high TMB that did not respond to anti-PD-1 therapy due to the diminished IFN-γ pathway and consequent lack of PD-L1 expression [108]. This evidence concerns the gene PDCD1 and melanoma.